301207Hualan VacSZSE

Hualan Biological Vaccine Inc.

华兰疫苗

301207

Shenzhen Stock Exchange

BoardChiNext of Shenzhen Stock Exchange
IndustryPharmaceutical Manufacturing
ISINCNE1000058J9
ListedFebruary 18, 2022
IR Emailhlym@hualan.com
Phone(+86)0373-3559909
Sourcecninfo.com.cn
AddressFu No. 1, Jia No. 1, Hualan Avenue, Xinxiang, Henan

Company Overview

Hualan Biological Vaccine Inc. is a high-tech enterprise founded in 2005, specializing in the research and development, production, and sales of vaccine products. The company is recognized as the largest influenza vaccine manufacturer in China and is notable for developing the world's first Influenza A (H1N1) vaccine. Hualan has achieved WHO pre-qualification for its influenza vaccine and holds an ISO quality system certificate, reflecting its commitment to quality, environmental, and safety management. Hualan's product portfolio includes over ten types of vaccines, covering viral, bacterial, and genetically engineered vaccines. The company operates six production lines for influenza vaccine bulk and eight filling lines, with a substantial annual production capacity. Hualan invests significantly in scientific research, dedicating 5-10% of its annual sales revenue to the development of new products. The company has established several core technology platforms and has undertaken multiple national projects, positioning itself as a key player in the vaccine industry and contributing to public health both domestically and globally.

AI-generated from company disclosures and CNInfo data.

Company Profile

Hualan Biological Bacterin Inc. is engaged in the research and development, production and sales of vaccines. Currently,Hualan has developed more than 10 kinds of products involving 3 major fields: viral vaccines, bacterial vaccines and genetically engineered vaccines. Hualan owns vaccine industrialization platforms and an emer gency research and development system enabling the quick and effective development and mass production of the vaccine against emerging infectious diseases. Hualan Bacterin currently has six production lines of influenza vaccine bulk and eight filling lines of influenz a vaccine. It can produce 400 million person doses of single-dose influenza vaccine and 100 million doses of quadrivalent influenza vaccine per year. Hualan biological influenza vaccine production capacity is the third in the world, and will play a critical role in the prevention of influenza epidemic in China and the world. The rapid and sustainable development of Hualan Vaccine relies on strong investment in scientific research. Hualan Vaccine spends 5-10%of its annual sales revenue on research and development of new products. The company has always adhered to independent research and development and the combination of industry-university-research. With the implementation of major national, provincial and municipal projects as the main focus, the company has broken through a number of key core technologies. The company has built core technology platforms such as "influenza virus vaccine research and development and large-scale production Technology Platform", "multi-conjugate and multivalent vaccine technology platform", "genetic engineering vaccine technology platform", "large-scale culture of mammalian cells and universal vaccine preparation technology platform", and promoted the company's core vaccine technology breakthrough and key process research, and promoted the transformation of major scientific and technological achievements. The company undertook 9 national major projects, including "Influenza virus vaccine emergency research and development system capacity building and product development", "Vaccine International Certification Construction Project", "Development and application of efficient separation and purification media". Relying on the advantages of the company's research and development technology platform, we constantly improve and optimize the production and preparation process, realize pipelining, automation and scale production process, and strictly control the purity, safety and titer of products in scale production, to ensure the safety and efficiency of products.

70 announcements tracked· Last: November 9, 2026

Key Financials

Revenue¥300.9M
Net Profit-¥4.5M
ROE-0.09%
Debt Ratio17.64%
Monetary Funds¥567.2M
Receivables¥911.6M
Total Shares601.0M

Announcements

70 totalCSV

Notes & Comments

Sign in to leave a comment or private note.

No notes or comments yet.